AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01056081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training.
Study NCT01674504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium chewable tablets 4 mg and 5 mg
Description: Montelukast sodium chewable tablets 4mg and 5mg
Study NCT01674504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium chewable tablets 4 mg and 5 mg
Description: Montelukast sodium chewable tablets 4mg and 5mg
Study NCT01466465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: given orally, once daily, before grass pollen season
Study NCT01466465 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: middle-chain fatty acids (carrier)
Description: given orally, once daily, before grass pollen season
Study NCT03225391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nap from 0:00 to 3:00 hours
Description: A nap from 0:00 to 3:00 hours during a night shift.
Study NCT03225391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nap from 3:00 to 6:00 hours
Description: A nap from 3:00 to 6:00 hours during a night shift.
Study NCT01136525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir Hydrochloride
Description: Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
Study NCT01136525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir Hydrochloride
Description: Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
Study NCT04242706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETTEvac
Description: Endotracheal tube with evacuation lumen without noble metal coating
Study NCT04242706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIP ETTEvac
Description: Endotracheal tube with evacuation lumen with noble metal coating
Study NCT00892008 — intervention group
Intervention type: DRUG
Intervention: Pregabalin
Description: Pregabalin 75-150 mg BID for at least 2 weeks.
Study NCT05130372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Relaxation Method Group- Roller Massage
Description: A theraband roller massager (Theraband®, The Hygenic Corporation, Akron, OH) was used for the myofascial relaxation method.
Study NCT04521309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody based IVIG therapy
Description: Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics
Study NCT00003851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gonzalez regimen
Study NCT01721343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participate in an individualized conditioning program with an RCM
Study NCT01721343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Undergo enhanced usual care with an RCM
Study NCT01752647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low dose computed tomography
Description: Low dose computed tomography scan
Study NCT00551031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)
Description: 0.1 mL, Intradermal (ID)
Study NCT00551031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)
Description: 0.1 mL, Intradermal (ID)
Study NCT00551031 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
Description: 0.5 mL, Intramuscular (IM)
Study NCT00551031 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
Description: 0.5 mL, Intramuscular (IM)
Study NCT05940506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826-2.5 mg (0.25%)/60 mL BID
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
Study NCT05940506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826-5 mg (5%)/60 mL QD
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.
Study NCT05940506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826-5 mg (5%)/60 mL BID
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
Study NCT05940506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm),starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily for QD dose groups, and once in the morning and once in the evening for the BID dose groups.
Study NCT00983866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Telephone Counseling
Description: The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
Study NCT01774812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Description: 0.25 mcg 3x per week for 6 weeks
Study NCT00003875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given PO or IV
Study NCT00003875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00003875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT00003875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous or syngeneic stem cell rescue
Study NCT03757351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL747
Description: Repeating oral dose
Study NCT03757351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Repeating oral dose
Study NCT01774812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: 50,000IU 1x per week for 6 weeks
Study NCT03722472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
Study NCT03722472 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ID93 + GLA-SE
Description: The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
Study NCT02877069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VYC-12 HA injectable gel
Description: VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
Study NCT00047502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib (SCH66336)
Description: Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.
Study NCT00047502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec)
Description: Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day.
Study NCT04009239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Consuming energy during a short interval during the day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: pyrazinamide
Description: pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: kanamycin
Description: kanamycin (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: amikacin
Description: amikacin (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: capreomycin
Description: capreomycin (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: moxifloxacin
Description: moxifloxacin (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: levoflaxacin
Description: levofloxacin (2nd line TB drug)
Study NCT00665678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: treatment for three months with paroxetine
Study NCT00665678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment for three months with placebo
Study NCT00323531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube with tPA infusion for 3 days
Description: fibrinolysis through the chest tube
Study NCT03357666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUDC_VT(Glucose 200mg/Sodium chloride 200mg)
Description: Vaginal administration, two tablets once a day for 7 days
Study NCT03357666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUDC_VT (Glucose 400mg/Sodium chloride 200mg)
Description: Vaginal administration, two tablets once a day for 7 days
Study NCT03357666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUDC_VT (Glucose 400mg)
Description: Vaginal administration, two tablets once a day for 7 days
Study NCT03357666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUDC_VT (Sodium chloride 200mg)
Description: Vaginal administration, two tablets once a day for 7 days
Study NCT03357666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal administration, two tablets once a day for 7 days
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: ofloxacin
Description: ofloxacin (2nd line TB drug)
Study NCT00323531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS decortication
Description: thoracoscopic decortication
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: ethionamide/prothionamide
Description: ethionamide/prothionamide (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: terizidone/cycloserine
Description: terizidone/cycloserine (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: para-aminosalicylic acid (PAS)
Description: para-aminosalicylic acid (PAS) (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: high dose INH
Description: high dose INH (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: bedaquiline
Description: bedaquiline (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: clofazamine
Description: clofazamine (2nd TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: delamanid
Description: delamanid (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: linezolid
Description: linezolid (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: pretomanid
Description: pretomanid (2nd line TB drug)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: ethinyl estradiol
Description: oral contraceptives formulated with 30-35 μg ethinyl estradiol
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: etonogestrel implant
Description: etonogestrel implant contraceptive
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: nevirapine
Description: nevirapine 200 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: amprenavir
Description: amprenavir 1200mg twice a day
Study NCT02174016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Study NCT01051115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
Study NCT01825226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced-Homestead Food Production Program
Description: Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
Study NCT00505804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
Study NCT00505804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Description: Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
Study NCT02185248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Action Plan
Description: The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
Study NCT03638557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritious Lunch
Description: The intervention package consists of the following;~1. Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~2. Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein
Study NCT03305757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artiss
Description: Application of ARTISS Glue to skin flaps after mastectomy
Study NCT03305757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vicryl sutures
Description: Flap fixation with vicryl sutures after mastectomy
Study NCT03305757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Conventional closure after mastectomy
Study NCT01721343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Undergo enhanced usual care with an RCM
Study NCT02866526 — intervention group
Intervention type: OTHER
Intervention: Patient questionnaire
Description: quantitative and qualitative data collection will be proposed.
Study NCT03487484 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaire for gastrointestinal tract
Description: To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
Study NCT03487484 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaire
Description: To assess quality of life, the SF-36 questionnaire will be applied
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: abacavir
Description: abacavir 300mg twice a day
Study NCT03487484 — intervention group
Intervention type: BEHAVIORAL
Intervention: Faecal Incontinence Score
Description: To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
Study NCT03383627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: * The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~* CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~* Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis.
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #2
Description: lopinavir/ritonavir (Kaletra) 400/100mg twice a day
Study NCT01297309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP558
Description: All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: indinavir/ritonavir dosage #1
Description: indinavir/ritonavir 800/100mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 700/100 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #3
Description: lopinavir/ritonavir (Kaletra) 533/133 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: atazanavir/ritonavir dosage #1
Description: atazanavir/ritonavir 300/100 mg once a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: didanosine delayed release (Videx® EC)
Description: didanosine delayed release (Videx® EC) 400 mg once a day if weight > 60 kg; 250 mg once a day if weight \< 60 kg
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: emtricitabine
Description: emtricitabine 200 mg once a day
Study NCT05020301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external meditation guided audio
Description: Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: tenofovir
Description: tenofovir 300 mg once a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: nelfinavir dosage #1
Description: nelfinavir \[625 mg tablets\] 1250 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: tipranavir/ritonavir
Description: tipranavir/ritonavir 500/200 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: lopinavir/ritonavir dosage #4
Description: lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: raltegravir
Description: raltegravir 400 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: etravirine
Description: etravirine 200 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: maraviroc
Description: maraviroc 150 mg or 300 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: atazanavir/ritonavir dosage #2
Description: atazanavir/ritonavir 400/100mg once a day